Consultation opens on guide to China for Australian medtech companies
20 November, 2014AusBiotech and an expert advisory panel have developed a draft 'China Guide' for Australian medtech companies and AusBiotech is now seeking comment.
CSL commences phase IIb heart attack trial
20 November, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) has launched a trial of CSL112 in patients at risk of recurrent cardiovascular events and presented data into the cholesterol-clearing mechanism of action behind the drug.
Prana's PBT2 generally tolerated in Huntington's trial
19 November, 2014 by Dylan Bushell-EmblingPrana Biotechnology (ASX:PRR) has published results of a trial of its PBT2 candidate in Huntington's disease showing it was generally well tolerated despite some adverse events.
Starpharma to get China patent for Priostar
18 November, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) will receive a Chinese formulation patent covering the use of its Priostar synthetic nanoscale dendrimers in agrochemical applications.
Review of medicines and medical devices regulation commences with forum
18 November, 2014A forum was held last week as the first step in the recently announced independent review of medicines and medical devices regulation. Attendees were advised that the review will commence with a discussion paper, which is expected to be launched by the end of the week, and the opening of the call for submissions.
Next-generation researchers recognised in the AbbVie Student Poster Awards
13 November, 2014The important research being conducted by Australia's graduate students has been featured in a poster display at the recent AusBiotech 2014 national conference, with the most outstanding being recognised with the AbbVie Student Poster Award.
CSL completes $500m placement
13 November, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) has completed a debt placement worth nearly $500m to help pay for capital management activities including its $900m share buyback.
Alchemia CEO leaves as Calzada gets a new one
13 November, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has announced the sudden departure of CEO Thomas Liquard, Calzada (ASX:CZD) has appointed a new CEO and Patrys (ASX:PAB) has added to its board.
Govt consults on boosting the commercial returns from research
11 November, 2014A key element of the Industry Innovation and Competitiveness Agenda has begun consultation, with the Australian Government releasing the discussion paper 'Boosting the Commercial Returns from Research'.
Bionomics gets approval for BNC210 trial
11 November, 2014 by Dylan Bushell-EmblingBionomics (ASX:BNO) has secured approval for a phase Ib trial of anxiety and depression drug candidate BNC210, and will soon apply to conduct a phase II trial in anxiety.
Innate commences dosing in SPMS trial
11 November, 2014 by Dylan Bushell-EmblingInnate Immunotherapeutics (ASX:IIL) is dosing patients in a phase IIb trial of its MIS416 candidate in secondary progressive multiple sclerosis, and plans to activate a third site tomorrow.
Global Kinetics adds former EMA head to board
10 November, 2014 by Dylan Bushell-EmblingFormer EMA chief Dr Thomas Lönngren has joined the board of Global Kinetics, to help the company commercialise its Parkinson's symptom monitoring device.
Meeting of leading minds at key summit to support Australia's advanced manufacturing
06 November, 2014A critical mass of Australian leaders will set their collective mind to support Australia's future manufacturing industry at a summit next week in Sydney.
CNS, BDC to join forces for biotech consulting
05 November, 2014 by Dylan Bushell-EmblingClinical Network Services has entered a partnership to expand its consultancy expertise, and has appointed a principal consultant for its new London office.
Medical devices on trial
05 November, 2014 by Susan WilliamsonMedical technology company Rhinomed is using its BreatheAssist technology platform to develop nasal devices for sport, snoring, sleep apnoea and drug delivery.
